SCHEMBL2569308

SCHEMBL2569308

CC(C)(C)OC(=O)C=CC#N

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.34
DGAT1 O75907 1/20 0.32
CTSS P25774 2/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrylic Acid SCHEMBL28308157 0.89 LMNA (0.36)
SCHEMBL667300 0.81 KEAP1 (0.31)
SCHEMBL43004 0.80 HCAR2 (0.45) DGAT1ALDH1A1
SCHEMBL43764 0.80 HCAR2 (0.45) DGAT1ALDH1A1
SCHEMBL375029 0.80 HCAR2 (0.45) DGAT1ALDH1A1
SCHEMBL11150713 0.79 ALDH1A1 (0.30) ALDH1A1
SCHEMBL28308158 0.79 HCAR2 (0.31)
SCHEMBL2970153 0.79 CTSK (0.35) CTSKDGAT1CTSS
SCHEMBL27638180 0.78 HCAR2 (0.43) DGAT1
SCHEMBL4891444 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717744-A1 USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE Bostik SA (FR) 2026-04-01 EP claimed
US-20250215132-A1 TWO-PART CURABLE COMPOSITION BOSTIK SA (FR) 2025-07-03 US claimed
EP-4504844-A1 TWO-PART CURABLE COMPOSITION Bostik SA (FR) 2025-02-12 EP claimed
US-20240240064-A1 TWO-PART CURABLE COMPOSITION BOSTIK SA (FR) 2024-07-18 US claimed
EP-4334368-A1 TWO-PART CURABLE COMPOSITION Bostik SA (FR) 2024-03-13 EP claimed
CN-117377706-A Two-part curable composition 博斯蒂克股份公司 2024-01-09 CN claimed
WO-2023194367-A1 TWO-PART CURABLE COMPOSITION BOSTIK SA (FR) 2023-10-12 WO claimed
EP-4257648-A1 TWO-PART CURABLE COMPOSITION Bostik SA (FR) 2023-10-11 EP claimed
WO-2022234017-A1 TWO-PART CURABLE COMPOSITION BOSTIK SA (FR) 2022-11-10 WO claimed
EP-4086294-A1 TWO-PART CURABLE COMPOSITION Bostik SA (FR) 2022-11-09 EP claimed
EP-1100380-B1 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTHCARE (US) 2011-11-02 EP claimed
EP-1100380-A4 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTHCARE (US) 2008-07-30 EP claimed
US-20040013614-A1 Acrylic-based adhesive composition BTG INTERNATIONAL LIMITED (GB) 2004-01-22 US claimed
EP-1341563-A1 ACRYLIC-BASED ADHESIVE COMPOSITION UNIVERSIDAD DE ALICANTE (ES) 2003-09-10 EP claimed
WO-2002009784-A1 ACRYLIC-BASED ADHESIVE COMPOSITION UNIVERSIDAD DE ALICANTE (ES) 2002-02-07 WO claimed
EP-1100380-A1 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTHCARE GROUP LP (US) 2001-05-23 EP claimed
WO-2000072761-A1 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTH CARE GROUP, LP (US) 2000-12-07 WO claimed
EP-4717744-A1 USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE Bostik SA (FR) 2026-04-01 EP disclosed
US-6183593-B1 CURABLE BLEND CLOSURE MEDICAL CORPORATION 2001-02-06 US disclosed
WO-2000072761-A1 BIOABSORBABLE BLENDS AND SURGICAL ARTICLES THEREFROM TYCO HEALTH CARE GROUP, LP (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040013614-A1 Acrylic-based adhesive composition C5AR1, C1R, COL2A1 CTSK 3924/4885DGAT1 2764/4885CTSS 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.